Biochem/Chemical Bio or Chem PhD for Biotech ER?

Based on the most helpful WSO content, both a Biochemistry/Chemical Biology PhD and a Chemistry PhD can be valuable for a career in biotech equity research. However, the choice depends on how you position yourself and the skills you develop during your PhD.

1. Biochemistry/Chemical Biology PhD: This path might provide a stronger foundation in molecular biology and biological systems, which are often directly relevant to evaluating biotech companies, especially those focused on drug development and biological therapies. It could give you an edge in understanding clinical and biological data.

2. Chemistry PhD: While it may not have as much direct biological focus, a Chemistry PhD can still be highly relevant, especially if you focus on areas like medicinal chemistry, drug design, or materials science for biotech applications. The key is to gain exposure to biotech-relevant topics and demonstrate your ability to analyze and understand scientific data.

Ultimately, the most important factors are: - Your ability to learn and adapt: As highlighted in WSO threads, you can gain biotech-specific knowledge by reading clinical data, scientific papers, and talking to experts. - Networking and diligence: Many successful professionals in biotech equity research have diverse academic backgrounds, and success often comes from networking, informational interviews, and demonstrating your analytical skills. - Passion and expertise: If you are more passionate about chemistry, pursuing a Chemistry PhD might be the better choice, as passion often translates into better performance and deeper expertise.

In summary, while a Biochemistry/Chemical Biology PhD might align more directly with biotech equity research, a Chemistry PhD is not a disadvantage if you tailor your experience and knowledge toward biotech applications.

Sources: Biotech finance part 2: valuation methodologies and modeling considerations, Biotech finance part 2: valuation methodologies and modeling considerations, Biotech finance: from IB to VC / HF to funded startup, Biotech equity research possible with ZERO finance experience?